Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis : Up to 5 years of follow-up in the DAYBREAK open-label extension trial
-
Cree, Bruce A. C (University of California)
;
Selmaj, Krzysztof W. (University of Warmia and Mazury in Olsztyn) ;
Steinman, Lawrence (Stanford University) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Bar-Or, Amit (University of Pennsylvania) ;
Arnold, Douglas Lorne (McGill University) ;
Hartung, Hans-Peter (Medical University of Vienna) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Kubala Havrdova, Eva (Charles University) ;
Sheffield, James K. (Bristol-Myers Squibb Company) ;
Minton, Neil (Bristol-Myers Squibb Company) ;
Cheng, Chun Yen (Bristol-Myers Squibb Company) ;
Silva, Diego (Bristol-Myers Squibb Company) ;
Kappos, Ludwig (University of Basel) ;
Cohen, Jeffrey A. (Cleveland Clinic) ;
Universitat Autònoma de Barcelona